Alaunos Therapeutics (NASDAQ:TCRT) Issues Quarterly Earnings Results

Alaunos Therapeutics (NASDAQ:TCRT) released its quarterly earnings data on Friday. The company reported ($0.41) EPS for the quarter, FiscalAI reports.

Alaunos Therapeutics Trading Down 3.0%

Shares of NASDAQ TCRT opened at $1.93 on Friday. The firm has a market cap of $47.13 million, a P/E ratio of -1.01 and a beta of -1.00. Alaunos Therapeutics has a 1-year low of $1.67 and a 1-year high of $4.59. The business’s 50 day moving average is $2.06 and its 200-day moving average is $2.56.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Alaunos Therapeutics stock. Geode Capital Management LLC grew its position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,736 shares of the company’s stock after buying an additional 3,945 shares during the period. Geode Capital Management LLC owned approximately 0.85% of Alaunos Therapeutics worth $64,000 at the end of the most recent quarter. 27.72% of the stock is owned by institutional investors and hedge funds.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.